Uli Hacksell
CEO at ACADIA Pharmaceuticals
📍 San Diego, California, United States
Uli Hacksell is a veteran pharmaceutical executive and board chairman with deep expertise in CNS drug development. As the former CEO of ACADIA Pharmaceuticals, he was instrumental in the development of NUPLAZID®, a breakthrough treatment for Parkinsons disease psychosis. He earned his Ph. D. from Uppsala University in Sweden.
He is a highly respected scientist, having co-authored more than 170 scientific papers and holding numerous patents.
Read the full overview →Experience
25 Years
Current Role
CEO
Job Level
Leadership
Location
San Diego, California, United States
Personality Overview
Personality insights not availableWe need more social data to generate the DISC analysis and selling playbook. The professional details below are still available.
Priorities
Topics Uli cares about
CNS Drug Development
His career has centered on creating novel therapeutics for central nervous system disorders, exemplified by his leadership in developing NUPLAZID at ACADIA Pharmaceuticals.
Biotech Board Governance
He currently serves as the Chairman of the Board for multiple biopharmaceutical companies, including Annexon Biosciences, indicating a focus on corporate strategy and oversight.
Career
Work history
9-2000
CEO
ACADIA Pharmaceuticals
In the press
Media appearances
ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D.. Featured in Acadia Pharmaceuticals (official press release)
See now
Education
Uli has no verified education history
Social presence
Other ACADIA Pharmaceuticals Employees
Explore more public profiles from related professionals.
More profiles
Discover additional public profiles from our index.
Search more profiles
Looking for someone else? Search here for anyone.